TY  - JOUR
AU  - Pavlov-Dolijanović, Slavica
AU  - Vujasinović-Stupar, Nada
AU  - Zugić, Vladimir
AU  - Ostojić, Predrag
AU  - Zeković, Ana
AU  - Živanović-Radnić, Tatjana
AU  - Jeremić, Ivan
AU  - Tadić, Ivana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3066
AB  - The study aims to analyze the effects of induction treatment with cyclophosphamide (CYC) pulse therapy followed by maintenance treatment with other mild immunosuppressive agents on lung function in scleroderma (SSc) patients. Thirty patients with SSc (mean age 52years, mean disease duration  lt 2years) with forced vital capacity (FVC) 80% and/or diffusing capacity of carbon monoxide (DLco) 70% were included. Monthly CYC pulses were given for 6months (induction treatment), followed by 3-monthly maintenance pulses for the next 18months, and during the next 5years patients received other mild immunosupressive therapy brought by the competent rheumatologist. The efficacy was evaluated by comparing FVC% and DLco% after 6, 24, and 84months from the baseline. All patients completed induction and maintenance treatment with CYC. Three patients were lost to follow-up. The rest of 27 patients, during the next 5years, received other immunosupressive agents (14 azathioprine, 9 methotrexate, and 4 mycophenolate mofetil). Three patients died in the 4years of follow-up. By 6, 24, and 84months, the mean FVC and DLco changes were +0.47 and +2.10, +3.30 and -2.49, and +1.53 and -3.76%, respectively. These changes were not significantly different from the baseline values. CYC does not appear to result in clinically significant improvement of pulmonary function but fulfilled criteria of stable disease. Maintenance treatment with other mild immunosupressive agents preserves the benefits achieved during CYC treatment.
PB  - Springer
T2  - Clinical Rheumatology
T1  - Long-term effects of immunosuppressive therapy on lung function in scleroderma patients
VL  - 37
IS  - 11
SP  - 3043
EP  - 3050
DO  - 10.1007/s10067-018-4266-0
ER  - 

@article{
author = "Pavlov-Dolijanović, Slavica and Vujasinović-Stupar, Nada and Zugić, Vladimir and Ostojić, Predrag and Zeković, Ana and Živanović-Radnić, Tatjana and Jeremić, Ivan and Tadić, Ivana",
year = "2018",
abstract = "The study aims to analyze the effects of induction treatment with cyclophosphamide (CYC) pulse therapy followed by maintenance treatment with other mild immunosuppressive agents on lung function in scleroderma (SSc) patients. Thirty patients with SSc (mean age 52years, mean disease duration  lt 2years) with forced vital capacity (FVC) 80% and/or diffusing capacity of carbon monoxide (DLco) 70% were included. Monthly CYC pulses were given for 6months (induction treatment), followed by 3-monthly maintenance pulses for the next 18months, and during the next 5years patients received other mild immunosupressive therapy brought by the competent rheumatologist. The efficacy was evaluated by comparing FVC% and DLco% after 6, 24, and 84months from the baseline. All patients completed induction and maintenance treatment with CYC. Three patients were lost to follow-up. The rest of 27 patients, during the next 5years, received other immunosupressive agents (14 azathioprine, 9 methotrexate, and 4 mycophenolate mofetil). Three patients died in the 4years of follow-up. By 6, 24, and 84months, the mean FVC and DLco changes were +0.47 and +2.10, +3.30 and -2.49, and +1.53 and -3.76%, respectively. These changes were not significantly different from the baseline values. CYC does not appear to result in clinically significant improvement of pulmonary function but fulfilled criteria of stable disease. Maintenance treatment with other mild immunosupressive agents preserves the benefits achieved during CYC treatment.",
publisher = "Springer",
journal = "Clinical Rheumatology",
title = "Long-term effects of immunosuppressive therapy on lung function in scleroderma patients",
volume = "37",
number = "11",
pages = "3043-3050",
doi = "10.1007/s10067-018-4266-0"
}

Pavlov-Dolijanović, S., Vujasinović-Stupar, N., Zugić, V., Ostojić, P., Zeković, A., Živanović-Radnić, T., Jeremić, I.,& Tadić, I.. (2018). Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. in Clinical Rheumatology
Springer., 37(11), 3043-3050.
https://doi.org/10.1007/s10067-018-4266-0

Pavlov-Dolijanović S, Vujasinović-Stupar N, Zugić V, Ostojić P, Zeković A, Živanović-Radnić T, Jeremić I, Tadić I. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. in Clinical Rheumatology. 2018;37(11):3043-3050.
doi:10.1007/s10067-018-4266-0 .

Pavlov-Dolijanović, Slavica, Vujasinović-Stupar, Nada, Zugić, Vladimir, Ostojić, Predrag, Zeković, Ana, Živanović-Radnić, Tatjana, Jeremić, Ivan, Tadić, Ivana, "Long-term effects of immunosuppressive therapy on lung function in scleroderma patients" in Clinical Rheumatology, 37, no. 11 (2018):3043-3050,
https://doi.org/10.1007/s10067-018-4266-0 . .

TY  - JOUR
AU  - Popević, Spasoje
AU  - Šumarac, Zorica
AU  - Jovanović, Dragana
AU  - Babić, Dragan
AU  - Stjepanović, Mihailo
AU  - Jovičić, Snežana
AU  - Sobić-Saranović, Dragana
AU  - Filipović, Snežana
AU  - Gvozdenović, Branko
AU  - Omcikus, Maja
AU  - Milovanović, Andela
AU  - Videnović-Ivanov, Jelica
AU  - Radović, Ana
AU  - Zugić, Vladimir
AU  - Vučinić-Mihailović, Violeta
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2749
AB  - Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study
VL  - 35
IS  - 4
SP  - 390
EP  - 400
DO  - 10.1515/jomb-2016-0017
ER  - 

@article{
author = "Popević, Spasoje and Šumarac, Zorica and Jovanović, Dragana and Babić, Dragan and Stjepanović, Mihailo and Jovičić, Snežana and Sobić-Saranović, Dragana and Filipović, Snežana and Gvozdenović, Branko and Omcikus, Maja and Milovanović, Andela and Videnović-Ivanov, Jelica and Radović, Ana and Zugić, Vladimir and Vučinić-Mihailović, Violeta",
year = "2016",
abstract = "Background: Until now, a proper biomarker(s) to evaluate sarcoidosis activity has not been recognized. The aims of this study were to evaluate the sensitivity and specificity of the two biomarkers of sarcoidosis activity already in use (serum angiotensin converting enzyme - ACE and serum chitotriosidase) in a population of 430 sarcoidosis patients. The activities of these markers were also analyzed in a group of 264 healthy controls. Methods: Four hundred and thirty biopsy positive sarcoidosis patients were divided into groups with active and inactive disease, and groups with acute or chronic disease. In a subgroup of 55 sarcoidosis patients, activity was also assessed by F-18 fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) scanning. Both serum chitotriosidase and ACE levels showed non-normal distribution, so nonparametric tests were used in statistical analysis. Results: Serum chitotriosidase activities were almost 6 times higher in patients with active sarcoidosis than in healthy controls and inactive disease. A serum chitotriosidase value of 100 nmol/mL/h had the sensitivity of 82.5% and specificity of 70.0%. A serum ACE activity cutoff value of 32.0 U/L had the sensitivity of 66.0% and the specificity of 54%. A statistically significant correlation was obtained between the focal granulomatous activity detected on F-18-FDG PET/CT and serum chitotriosidase levels, but no such correlation was found with ACE. The levels of serum chitotriosidase activity significantly correlated with the disease duration (P lt 0.0001). Also, serum chitotriosidase significantly correlated with clinical outcome status (COS) categories (rho=0.272, P=0.001). Conclusions: Serum chitotriosidase proved to be a reliable biomarker of sarcoidosis activity and disease chronicity.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study",
volume = "35",
number = "4",
pages = "390-400",
doi = "10.1515/jomb-2016-0017"
}

Popević, S., Šumarac, Z., Jovanović, D., Babić, D., Stjepanović, M., Jovičić, S., Sobić-Saranović, D., Filipović, S., Gvozdenović, B., Omcikus, M., Milovanović, A., Videnović-Ivanov, J., Radović, A., Zugić, V.,& Vučinić-Mihailović, V.. (2016). Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 35(4), 390-400.
https://doi.org/10.1515/jomb-2016-0017

Popević S, Šumarac Z, Jovanović D, Babić D, Stjepanović M, Jovičić S, Sobić-Saranović D, Filipović S, Gvozdenović B, Omcikus M, Milovanović A, Videnović-Ivanov J, Radović A, Zugić V, Vučinić-Mihailović V. Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study. in Journal of Medical Biochemistry. 2016;35(4):390-400.
doi:10.1515/jomb-2016-0017 .

Popević, Spasoje, Šumarac, Zorica, Jovanović, Dragana, Babić, Dragan, Stjepanović, Mihailo, Jovičić, Snežana, Sobić-Saranović, Dragana, Filipović, Snežana, Gvozdenović, Branko, Omcikus, Maja, Milovanović, Andela, Videnović-Ivanov, Jelica, Radović, Ana, Zugić, Vladimir, Vučinić-Mihailović, Violeta, "Verifying Sarcoidosis Activity: Chitotriosidase Versus ACE in Sarcoidosis - A Case-Control Study" in Journal of Medical Biochemistry, 35, no. 4 (2016):390-400,
https://doi.org/10.1515/jomb-2016-0017 . .